Investors
GSK delivers full year and Q4 2022 Results
Investors
We have announced our full year and Q4 2022 Results
Press releases
- Jesduvroq (daprodustat) approved by US FDA for anemia of chronic kidney disease in adults on dialysis
- Benlysta granted Orphan Drug Designation by US FDA for the potential treatment of systemic sclerosis
- New data at ASH underscore the potential for durable, clinically important responses with momelotinib for myelofibrosis patients


Choose your path
By bringing outstanding people together in an inclusive environment to do work that matters, we can impact the world’s health.
GSKUS on twitter
GSK Global links
Visit our Global site for additional features